Info
- Utilizzare la checkbox di selezione a fianco di ciascun documento per attivare le funzionalità di stampa, invio email, download nei formati disponibili del (i) record.
Cancer drug safety and public health policy : a changing landscape / / Charles Bennett, Courtney Lubaczewski, Bartlett Witherspoon, editors
| Cancer drug safety and public health policy : a changing landscape / / Charles Bennett, Courtney Lubaczewski, Bartlett Witherspoon, editors |
| Pubbl/distr/stampa | Cham, Switzerland : , : Springer, , [2022] |
| Descrizione fisica | 1 online resource (171 pages) |
| Disciplina | 616.99406 |
| Collana | Cancer treatment and research |
| Soggetto topico |
Cancer - Treatment
Medical policy Oncology Antineoplastic Agents - standards Neoplasms - drug therapy |
| ISBN | 3-031-04402-9 |
| Formato | Materiale a stampa  |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto |
Intro -- Preface -- Contents -- Editors and Contributors -- 1 Fluoroquinolone-Associated Disability and Other Fluoroquinolone-Associated Serious Adverse Events: Unexpected Toxicities Have Emerged in Recent Years -- 1.1 Introduction -- 1.1.1 FQ Adverse Event Drug Label Warnings -- 1.1.2 FQ Drug Label Changes (See Table 1.1 for Levofloxacin Label Changes) -- 1.1.3 FDA Reports of FQ Adverse Events -- 1.1.4 November 5, 2015, FDA Advisory Committee Meeting Identifies FQAD -- 1.1.5 November 5, 2015, FDA Advisory Committee Votes -- 1.1.6 Boxwell FDA FQ Data Compared with Social Media FQ Reports -- 1.1.7 Gender -- 1.1.8 Specific FQs -- 1.1.9 Duration of FQAD -- 1.1.10 FQAD: Reasons for Which FQ was Prescribed -- 1.1.11 FQAD Specific Events -- 1.1.12 Possible Mechanism of FQ Toxicities -- 1.1.13 Another Possible Pathophysiologic Mechanism: Matrix Metalloproteinase Toxicity -- 1.1.14 FQ-Associated Peripheral Neuropathy -- 1.1.15 Levaquin Clinical Trials Completed Prior to FDA Approval in 1997 -- 1.1.16 2001 FDA FQ Review -- 1.1.17 2003 FDA FQ Review -- 1.1.18 2008 FDA Pediatric Levofloxacin Review -- 1.1.19 2010 Pfizer Report -- 1.1.20 2011 Levaquin Postmarketing Review -- 1.1.21 2013 FDA Review -- 1.1.22 2014-Present Media Reports Regarding FQs -- 1.1.23 2014 FDA Advisory Committee Comments -- 1.1.24 2014 FDA Dear Healthcare Professional Letters -- 1.1.25 2014 Citizen Petition -- 1.1.26 2014 Meeting with U.S. Senate Health Committee -- 1.1.27 2015 Meeting with FDA -- 1.1.28 2015 FQ Case Studies -- 1.1.29 2015 FDA Advisory Committee Meeting -- 1.1.30 2015 FDA Listening Session -- 1.1.31 2016 FQ Neuropsychiatric Study -- 1.1.32 2016 FQ Label Updates -- 1.1.33 2016 FDA Response to Citizen Petition -- 1.1.34 2018 FQ Nature Article -- 1.1.35 2019 Citizen Petition -- 1.1.36 2019 FQ Neuropsychiatric Toxicity Study -- 1.2 Discussion -- 1.3 Conclusions.
1.3.1 Recommendations -- 1.3.2 Significance of This FQ Study -- 1.4 REMS Request -- References -- 2 Biosimilar Epoetin in the United States: A View from the Southern Network on Adverse Reactions -- 2.1 Introduction -- 2.1.1 Regulatory Approval for Epoetin Biosimilar in the United States -- 2.1.2 Chemistry, Manufacturing, and Controls -- 2.1.3 Biological Activity -- 2.1.4 Pharmacology/Toxicology -- 2.1.5 Immunogenicity -- 2.1.6 Clinical Pharmacology -- 2.1.7 Clinical Efficacy and Safety -- 2.1.8 Risk Evaluation and Mitigations Strategy (REMS) -- 2.1.9 Extrapolation -- 2.1.10 Findings of the Oncology Drug Advisory Committee (ODAC) of the FDA -- 2.1.11 Patents and Litigation -- 2.1.12 Naming and Labeling -- 2.1.13 Interchangeability -- 2.1.14 Substitution -- 2.1.15 Pharmacovigilance and Immunogenicity -- 2.1.16 Lessons from the European Union (EU) Countries -- 2.1.17 Lessons from Japan -- 2.2 Conclusions -- References -- 3 Policing of Drug Safety Information Dissemination Under the False Claims Act -- 3.1 Introduction -- 3.1.1 The Settlement -- 3.1.2 Lessons Learned and Legal Precedent -- 3.1.3 Future of Policing Drug Safety Efforts -- 3.2 Conclusion -- References -- 4 Translating Research into Health Policy: The Citizen Petition Experience with the Food and Drug Administration -- 4.1 Introduction -- 4.1.1 The Citizen Petitions -- 4.2 Conclusions -- 4.2.1 Policy Implications -- References -- 5 Systemic Barriers and Potential Concerns from Reporting Serious Adverse Drug Reactions -- 5.1 Introduction -- 5.2 Findings of Litigation Risks -- 5.2.1 Fear of Being Included in a Lawsuit Against the Manufacturer -- 5.2.2 Fear of Being Sued for Libel -- 5.2.3 Fear of Personally Being Sued for Malpractice -- 5.2.4 Fear of Physician Partners Being Sued for Malpractice -- 5.3 Professional Retaliation. 5.3.1 Fear of Exclusion from Cooperative Industry-Sponsored Clinical Trials -- 5.3.2 Fear of Jeopardizing Existing Academic Collaborations -- 5.3.3 Fear of Being Excluded from a Pharmaceutical Corporation's Speaker's Bureau -- 5.4 Regulatory Considerations -- 5.4.1 Concern that no Response from the FDA Was Likely -- 5.4.2 Concern that no Response from the FDA Was Needed -- 5.5 Discussion -- References -- 6 Was There Something Rotten in Denmark: Nephrogenic System Fibrosis Cases Occurring in Copenhagen -- 6.1 Introduction -- 6.1.1 European Actions -- 6.1.2 Actions of the Manufacturer of Gadodiamide -- 6.2 Basic Science Considerations -- 6.3 Explanations for the Danish Findings -- 6.4 International Considerations -- 6.5 Summary -- References -- 7 Rituximab-Associated Progressive Multifocal Leukoencephalopathy: A Twenty-Year Update -- 7.1 Introduction -- 7.2 Methods -- 7.3 Results -- 7.4 Case Series -- 7.4.1 Periodic Safety Update Report, Global Safety Database, EudraViglinance Database, and FAERS Database -- 7.5 Epidemiologic Studies -- 7.5.1 PML-Related Safety Notifications from Market Authorization Holders for Rituximab in the US and Europe -- 7.6 Discussion -- References -- 8 Maximum Accuracy Machine Learning Statistical Analysis-A Novel Approach -- 8.1 Introduction -- 8.1.1 Data Analysis in Practice -- 8.1.2 Logistic Regression (MELR) Analysis -- 8.1.3 Using ODA to Maximize the Accuracy of the MELR Model -- 8.1.4 Novometric CTA Models Explicitly Maximizing ESS -- 8.2 Conclusion -- References -- 9 Investigating Severe Adverse Reactions: Examples of the ANTICIPATE Methodology at Work -- 9.1 Introduction -- 9.1.1 The Toxicities -- 9.1.2 HX575-Associated PRCA -- 9.1.3 Gadodiamide-Induced Nephrogenic Systemic Fibrosis -- 9.1.4 Peginesatide-Associated Anaphylaxis -- 9.2 The ANTICIPATE Evaluation -- 9.2.1 Signal Detection -- 9.3 sADR Data Analysis. 9.3.1 Root Cause Analyses/Toxicity Eradication -- 9.4 Conclusion -- References -- 10 Consequences to Patients, Clinicians, and Manufacturers When Very Serious Adverse Drug Reactions Are Identified (1997-2019): A Qualitative Analysis from the Southern Network on Adverse Reactions (SONAR) -- 10.1 Introduction -- 10.2 Methods -- 10.3 Results -- 10.4 Clinical and Economic Impact -- 10.5 Harms to Clinicians -- 10.6 Harms to Manufacturers, Actions by Regulatory Agencies, Financial Payments, and Attempts to Discredit Physicians -- 10.7 Discussion -- References -- 11 Moderna, Pfizer-BioNTech, and Johnson & -- Johnson/Janssen Post-Covid Vaccine Hematological Adverse Events Including Cerebral Venous Sinus Thrombosis (CVST), Thrombotic Thrombocytopenia (VITT), Blood Clots, Increased Vaginal/Menstrual Bleeding and/or Miscarriage, Stillbirth Delivery, or Premature Birth -- 11.1 Introduction -- 11.1.1 Study Implementation -- 11.2 Methods -- 11.3 Results -- 11.3.1 Blood Clot Related Events -- 11.3.2 Vaginal/Menstrual Bleeding AEs -- 11.3.3 Miscarriage, Stillbirth Delivery, or Premature Birth AEs -- 11.4 Conclusions -- 12 Investigating Novel Genetic Markers for Fluoroquinolone Associated Disorders -- 12.1 Introduction -- 12.1.1 Timeline of Events -- 12.1.2 Background of CYP2D6 -- 12.2 Conclusion -- References -- Index. |
| Record Nr. | UNINA-9910633932303321 |
| Cham, Switzerland : , : Springer, , [2022] | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Cancer management and research
| Cancer management and research |
| Pubbl/distr/stampa | [Auckland, N.Z.], : Dove Medical Press, ©2009- |
| Disciplina | 616.994005 |
| Soggetto topico |
Cancer
Cancer - Treatment Antineoplastic Agents Medical Oncology Neoplasms Neoplasms - drug therapy Neoplasms - prevention & control Neoplasms - radiotherapy Neoplasms - therapy Radiation Oncology |
| Soggetto genere / forma |
Periodical
Periodicals. |
| Soggetto non controllato | Oncology |
| Formato | Materiale a stampa |
| Livello bibliografico | Periodico |
| Lingua di pubblicazione | eng |
| Record Nr. | UNISA-996214167803316 |
| [Auckland, N.Z.], : Dove Medical Press, ©2009- | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. di Salerno | ||
| ||
Cancer management and research
| Cancer management and research |
| Pubbl/distr/stampa | [Auckland, N.Z.], : Dove Medical Press, ©2009- |
| Disciplina | 616.994005 |
| Soggetto topico |
Cancer
Cancer - Treatment Antineoplastic Agents Medical Oncology Neoplasms Neoplasms - drug therapy Neoplasms - prevention & control Neoplasms - radiotherapy Neoplasms - therapy Radiation Oncology |
| Soggetto genere / forma |
Periodical
Periodicals. |
| Soggetto non controllato | Oncology |
| Formato | Materiale a stampa |
| Livello bibliografico | Periodico |
| Lingua di pubblicazione | eng |
| Record Nr. | UNINA-9910143110003321 |
| [Auckland, N.Z.], : Dove Medical Press, ©2009- | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Cancer management and therapy / / Amal Hamza, Neveen Salem, editors
| Cancer management and therapy / / Amal Hamza, Neveen Salem, editors |
| Pubbl/distr/stampa | [Place of publication not identified] : , : IntechOpen, , [2018] |
| Descrizione fisica | 1 online resource (210 pages) : illustrations |
| Disciplina | 616.99406 |
| Soggetto topico | Cancer - Treatment |
| ISBN |
1-83881-301-2
1-78923-299-6 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Record Nr. | UNINA-9910317812903321 |
| [Place of publication not identified] : , : IntechOpen, , [2018] | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Cancer management with Chinese medicine [[electronic resource] /] / Yu Rencun, Hong Hai
| Cancer management with Chinese medicine [[electronic resource] /] / Yu Rencun, Hong Hai |
| Autore | Rencun Yu |
| Pubbl/distr/stampa | Singapore, : World Scientific Pub. Co., 2012 |
| Descrizione fisica | 1 online resource (223 p.) |
| Disciplina | 616.99406 |
| Altri autori (Persone) | HongHai |
| Soggetto topico |
Medicine, Chinese
Cancer - Treatment |
| Soggetto genere / forma | Electronic books. |
| ISBN |
1-280-66980-2
9786613646736 981-4374-75-X |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto |
CONTENTS; About the Authors; Preface; 1. Introduction (Hong Hai) The TCM Approach to Cancer Management; The TCM Approach to Cancer Management; 2. Principles of Diagnosis and Therapy in Traditional Chinese Medicine (Hong Hai); 2.1. Origins of Chinese Medical Theory; 2.2. The Establishment of Traditional Chinese Medicine; 2.3. Core Concepts and Entities in TCM; 2.3.1. The body's three essential substances: qi, blood and jinye; 2.3.1.1. Qi; 2.3.1.2. Blood; 2.3.1.3. Body fluids; 2.3.2. Channels and collaterals; 2.3.3. The organ systems; 2.4. Models for Analysis and Diagnosis of Illness
2.4.1. The yin-yang model2.4.2. Causes of illness; 2.4.3. Differentiating syndromes and applying therapy; 2.4.4. Diagnostic model of the four examinations; 2.4.4.1. Visual observation; 2.4.4.2. Listening and olfaction; 2.4.4.3. Inquiry; 2.4.4.4. Pulse-taking and palpation; 2.4.5. Principles of health and therapy in TCM; 2.5. TCM as Science; 3. Herbs and Prescriptions for Therapy (Hong Hai); 3.1. Chinese Materia Medica; 3.2. Preparation and Consumption of Herbs for Medicinal Use; 3.2.1. Processing of herbs; 3.3. Contraindications and Toxicities; 3.4. Classification of Herbs 3.4.1. Classification of herbs by natural characteristics3.4.2. Classification of herbs by therapeutic effects; 3.5. Chinese Medical Prescriptions; 4. Cancer Prevention and Treatment Using TCM (Yu Rencun*); 4.1. Avoidance of Factors Contributing to Higher Incidence of Cancers; 4.2. Healthy Living for Cancer Prevention; 4.3. Principles of Using TCM in Cancer Treatment; 4.3.1. Patients who have undergone radiotherapy; 4.3.2. Patients who have undergone chemotherapy; 4.3.3. Patients who have undergone surgery; 4.3.3.1. Pre-surgery care with TCM; 4.3.3.2. Post-surgery treatment 4.3.3.3. Post-surgery treatment with TCM in the longer term4.4. Combining Western Medical and TCM Treatments; 4.5. Preserving Life or Eliminating the Illness?; 5. Major Forms of Cancer and Case Studies (Yu Rencun*); 5.1. Lung Cancer; 5.2. Breast Cancer; 5.2.1. Treatment of breast cancer; 5.3. Liver Cancer; 5.3.1. TCM treatment by differentiating syndromes; 5.4. Colorectal Cancer; 5.5. Stomach Cancer; 6. Diet, Exercise and Health Cultivation (Hong Hai & Yu Rencun); 6.1. Nutrition in Cancer Prevention; 6.2. Nutritional Therapy for Cancer Patients 6.3. TCM Perspectives of Appropriate Diets for Cancer Patients6.4. Dietary Restrictions; 6.5. Exercise and Life Cultivation; References; Appendix 1: Herbs Used in Cancer Therapy; Appendix 2: Common Foods with Anti-Cancer Effects; Index |
| Record Nr. | UNINA-9910451622503321 |
Rencun Yu
|
||
| Singapore, : World Scientific Pub. Co., 2012 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Cancer management with Chinese medicine [[electronic resource] /] / Yu Rencun, Hong Hai
| Cancer management with Chinese medicine [[electronic resource] /] / Yu Rencun, Hong Hai |
| Autore | Rencun Yu |
| Pubbl/distr/stampa | Singapore, : World Scientific Pub. Co., 2012 |
| Descrizione fisica | 1 online resource (223 p.) |
| Disciplina | 616.99406 |
| Altri autori (Persone) | HongHai |
| Soggetto topico |
Medicine, Chinese
Cancer - Treatment |
| ISBN |
1-280-66980-2
9786613646736 981-4374-75-X |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto |
CONTENTS; About the Authors; Preface; 1. Introduction (Hong Hai) The TCM Approach to Cancer Management; The TCM Approach to Cancer Management; 2. Principles of Diagnosis and Therapy in Traditional Chinese Medicine (Hong Hai); 2.1. Origins of Chinese Medical Theory; 2.2. The Establishment of Traditional Chinese Medicine; 2.3. Core Concepts and Entities in TCM; 2.3.1. The body's three essential substances: qi, blood and jinye; 2.3.1.1. Qi; 2.3.1.2. Blood; 2.3.1.3. Body fluids; 2.3.2. Channels and collaterals; 2.3.3. The organ systems; 2.4. Models for Analysis and Diagnosis of Illness
2.4.1. The yin-yang model2.4.2. Causes of illness; 2.4.3. Differentiating syndromes and applying therapy; 2.4.4. Diagnostic model of the four examinations; 2.4.4.1. Visual observation; 2.4.4.2. Listening and olfaction; 2.4.4.3. Inquiry; 2.4.4.4. Pulse-taking and palpation; 2.4.5. Principles of health and therapy in TCM; 2.5. TCM as Science; 3. Herbs and Prescriptions for Therapy (Hong Hai); 3.1. Chinese Materia Medica; 3.2. Preparation and Consumption of Herbs for Medicinal Use; 3.2.1. Processing of herbs; 3.3. Contraindications and Toxicities; 3.4. Classification of Herbs 3.4.1. Classification of herbs by natural characteristics3.4.2. Classification of herbs by therapeutic effects; 3.5. Chinese Medical Prescriptions; 4. Cancer Prevention and Treatment Using TCM (Yu Rencun*); 4.1. Avoidance of Factors Contributing to Higher Incidence of Cancers; 4.2. Healthy Living for Cancer Prevention; 4.3. Principles of Using TCM in Cancer Treatment; 4.3.1. Patients who have undergone radiotherapy; 4.3.2. Patients who have undergone chemotherapy; 4.3.3. Patients who have undergone surgery; 4.3.3.1. Pre-surgery care with TCM; 4.3.3.2. Post-surgery treatment 4.3.3.3. Post-surgery treatment with TCM in the longer term4.4. Combining Western Medical and TCM Treatments; 4.5. Preserving Life or Eliminating the Illness?; 5. Major Forms of Cancer and Case Studies (Yu Rencun*); 5.1. Lung Cancer; 5.2. Breast Cancer; 5.2.1. Treatment of breast cancer; 5.3. Liver Cancer; 5.3.1. TCM treatment by differentiating syndromes; 5.4. Colorectal Cancer; 5.5. Stomach Cancer; 6. Diet, Exercise and Health Cultivation (Hong Hai & Yu Rencun); 6.1. Nutrition in Cancer Prevention; 6.2. Nutritional Therapy for Cancer Patients 6.3. TCM Perspectives of Appropriate Diets for Cancer Patients6.4. Dietary Restrictions; 6.5. Exercise and Life Cultivation; References; Appendix 1: Herbs Used in Cancer Therapy; Appendix 2: Common Foods with Anti-Cancer Effects; Index |
| Record Nr. | UNINA-9910779285103321 |
|
Rencun Yu
|
||
| Singapore, : World Scientific Pub. Co., 2012 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Cancer management with Chinese medicine [[electronic resource] /] / Yu Rencun, Hong Hai
| Cancer management with Chinese medicine [[electronic resource] /] / Yu Rencun, Hong Hai |
| Autore | Rencun Yu |
| Edizione | [1st ed.] |
| Pubbl/distr/stampa | Singapore, : World Scientific Pub. Co., 2012 |
| Descrizione fisica | 1 online resource (223 p.) |
| Disciplina | 616.99406 |
| Altri autori (Persone) | HongHai |
| Soggetto topico |
Medicine, Chinese
Cancer - Treatment |
| ISBN |
1-280-66980-2
9786613646736 981-4374-75-X |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto |
CONTENTS; About the Authors; Preface; 1. Introduction (Hong Hai) The TCM Approach to Cancer Management; The TCM Approach to Cancer Management; 2. Principles of Diagnosis and Therapy in Traditional Chinese Medicine (Hong Hai); 2.1. Origins of Chinese Medical Theory; 2.2. The Establishment of Traditional Chinese Medicine; 2.3. Core Concepts and Entities in TCM; 2.3.1. The body's three essential substances: qi, blood and jinye; 2.3.1.1. Qi; 2.3.1.2. Blood; 2.3.1.3. Body fluids; 2.3.2. Channels and collaterals; 2.3.3. The organ systems; 2.4. Models for Analysis and Diagnosis of Illness
2.4.1. The yin-yang model2.4.2. Causes of illness; 2.4.3. Differentiating syndromes and applying therapy; 2.4.4. Diagnostic model of the four examinations; 2.4.4.1. Visual observation; 2.4.4.2. Listening and olfaction; 2.4.4.3. Inquiry; 2.4.4.4. Pulse-taking and palpation; 2.4.5. Principles of health and therapy in TCM; 2.5. TCM as Science; 3. Herbs and Prescriptions for Therapy (Hong Hai); 3.1. Chinese Materia Medica; 3.2. Preparation and Consumption of Herbs for Medicinal Use; 3.2.1. Processing of herbs; 3.3. Contraindications and Toxicities; 3.4. Classification of Herbs 3.4.1. Classification of herbs by natural characteristics3.4.2. Classification of herbs by therapeutic effects; 3.5. Chinese Medical Prescriptions; 4. Cancer Prevention and Treatment Using TCM (Yu Rencun*); 4.1. Avoidance of Factors Contributing to Higher Incidence of Cancers; 4.2. Healthy Living for Cancer Prevention; 4.3. Principles of Using TCM in Cancer Treatment; 4.3.1. Patients who have undergone radiotherapy; 4.3.2. Patients who have undergone chemotherapy; 4.3.3. Patients who have undergone surgery; 4.3.3.1. Pre-surgery care with TCM; 4.3.3.2. Post-surgery treatment 4.3.3.3. Post-surgery treatment with TCM in the longer term4.4. Combining Western Medical and TCM Treatments; 4.5. Preserving Life or Eliminating the Illness?; 5. Major Forms of Cancer and Case Studies (Yu Rencun*); 5.1. Lung Cancer; 5.2. Breast Cancer; 5.2.1. Treatment of breast cancer; 5.3. Liver Cancer; 5.3.1. TCM treatment by differentiating syndromes; 5.4. Colorectal Cancer; 5.5. Stomach Cancer; 6. Diet, Exercise and Health Cultivation (Hong Hai & Yu Rencun); 6.1. Nutrition in Cancer Prevention; 6.2. Nutritional Therapy for Cancer Patients 6.3. TCM Perspectives of Appropriate Diets for Cancer Patients6.4. Dietary Restrictions; 6.5. Exercise and Life Cultivation; References; Appendix 1: Herbs Used in Cancer Therapy; Appendix 2: Common Foods with Anti-Cancer Effects; Index |
| Record Nr. | UNINA-9910824986103321 |
|
Rencun Yu
|
||
| Singapore, : World Scientific Pub. Co., 2012 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Cancer nanotechnology [[electronic resource] ] : going small for big advances
| Cancer nanotechnology [[electronic resource] ] : going small for big advances |
| Pubbl/distr/stampa | Bethesda, MD : , : National Cancer Institute, , 2004 |
| Descrizione fisica | 1 online resource (22 pages) : illustrations |
| Collana | NIH Publication |
| Soggetto topico |
Cancer - Diagnosis
Cancer - Prevention Cancer - Treatment Nanotechnology |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Altri titoli varianti | Cancer nanotechnology |
| Record Nr. | UNINA-9910700560403321 |
| Bethesda, MD : , : National Cancer Institute, , 2004 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Cancer nanotheranostics : what have we learned so far? / / edited by João Conde, Pedro Viana Baptista, Jesús M. De La Fuente and Furong Tian
| Cancer nanotheranostics : what have we learned so far? / / edited by João Conde, Pedro Viana Baptista, Jesús M. De La Fuente and Furong Tian |
| Autore | Pedro Viana Baptista |
| Pubbl/distr/stampa | Frontiers Media SA, 2016 |
| Descrizione fisica | 1 online resource (128 pages) : illustrations (chiefly colour); digital file(s) |
| Disciplina | 616.99406 |
| Collana |
Frontiers in Chemistry
Frontiers Research Topics |
| Soggetto topico |
Cancer - Treatment
Nanostructured materials - Health aspects |
| Soggetto non controllato |
Nanoparticles
Gene Therapy Immunotherapy bioimaging theranostics nanomaterials Drug delivery Nanomedicine Cancer Phototherapy |
| ISBN | 9782889197767 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Record Nr. | UNINA-9910136799803321 |
|
Pedro Viana Baptista
|
||
| Frontiers Media SA, 2016 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Cancer nursing [[electronic resource] ] : care in context / / edited by Jessica Corner and Christopher Bailey
| Cancer nursing [[electronic resource] ] : care in context / / edited by Jessica Corner and Christopher Bailey |
| Edizione | [2nd ed.] |
| Pubbl/distr/stampa | Oxford ; ; Malden, MA, : Blackwell Pub., c2008 |
| Descrizione fisica | 1 online resource (736 p.) |
| Disciplina | 616.99/40231 |
| Altri autori (Persone) |
CornerJessica
BaileyChristopher |
| Soggetto topico |
Cancer - Nursing
Cancer - Treatment |
| Soggetto genere / forma | Electronic books. |
| ISBN |
1-282-11686-X
9786612116865 1-4443-0925-0 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto |
Contents; Contributors; Foreword; Preface; Part 1: Cancer, Care, and Society; CHAPTER ONE: What is cancer?; CHAPTER TWO: Knowledge and caring: a philosophical and personal perspective; CHAPTER THREE: Cancer, care, and society; CHAPTER FOUR: Cancer epidemiology; CHAPTER FIVE: Developments in the management of cancer; Part 2: The Experience of Cancer; Introduction; CHAPTER SIX: The impact of cancer; CHAPTER SEVEN: The impact of cancer on the family; CHAPTER EIGHT: The impact of cancer on health care professionals; CHAPTER NINE: Therapeutic strategies in cancer care
Part 3: The Experience of Treatment Introduction; CHAPTER TEN: The experience of treatment; CHAPTER ELEVEN: Surgery; CHAPTER TWELVE: Chemotherapy; CHAPTER THIRTEEN: Radiotherapy; CHAPTER FOURTEEN: Endocrine therapies; CHAPTER FIFTEEN: Complementary and alternative therapies in cancer care; CHAPTER SIXTEEN: Hereditary cancer; Part 4: The Management of Cancer-related Problems; Introduction; CHAPTER SEVENTEEN: Pain; CHAPTER EIGHTEEN: Nausea and vomiting; CHAPTER NINETEEN: Fatigue; CHAPTER TWENTY: Breathlessness; CHAPTER TWENTY-ONE: Wound management; CHAPTER TWENTY-TWO: Lymphoedema CHAPTER TWENTY-THREE: Malignant ascites CHAPTER TWENTY-FOUR: Bone marrow suppression: neutropenia and thrombocytopenia; CHAPTER TWENTY-FIVE: Change in eating habits; CHAPTER TWENTY-SIX: Sexuality and cancer; CHAPTER TWENTY-SEVEN: Anxiety and depression; CHAPTER TWENTY-EIGHT: Delirium; CHAPTER TWENTY-NINE: Acute events in cancer; Part 5: Needs and Priorities in Cancer Care; Introduction; CHAPTER THIRTY: The needs of children and adolescents; CHAPTER THIRTY-ONE: The needs of older people; CHAPTER THIRTY-TWO: Ethnicity, difference, and care CHAPTER THIRTY-THREE: Living with cancer long term: the implications of survival CHAPTER THIRTY-FOUR: Self-management and self-help; CHAPTER THIRTY-FIVE: User involvement in cancer services; CHAPTER THIRTY-SIX: Palliative care and cancer; CHAPTER THIRTY-SEVEN: Research and cancer care; Index |
| Record Nr. | UNINA-9910454633703321 |
| Oxford ; ; Malden, MA, : Blackwell Pub., c2008 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Soggetto topico
-
Cancer - Treatment
(391)
- Cancer (51)
- Neoplasms - therapy (47)
- Neoplasms (40)
- Oncology (36)